Trial Profile
A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59 (R) Adjuvant
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus H7N9 vaccine Seqirus (Primary) ; MF 59
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 18 Jun 2020 Status changed from active, no longer recruiting to completed.
- 21 Nov 2019 Planned End Date changed from 30 Nov 2019 to 22 Apr 2020.
- 21 Nov 2019 Planned primary completion date changed from 30 Nov 2019 to 22 Apr 2020.